Antineoplastic combinations comprising cci-779 ( rapamycin derivative) together with gemcitabine or fluorouracil

摘要

The invention provides the use of a combination of an mTOR inhibitor such as a rapamycin and an antimetabolite antineoplastic agent such as gemsitabine or fluorouracil in the treatment of neoplasms.